<DOC>
	<DOCNO>NCT00003213</DOCNO>
	<brief_summary>RATIONALE : Antiemetic drug may help reduce prevent nausea vomit patient treated chemotherapy . It know whether receive dexamethasone granisetron effective receive dexamethasone metoclopramide reduce side effect chemotherapy . PURPOSE : Randomized phase III trial compare effectiveness dexamethasone either granisetron metoclopramide patient treat chemotherapy .</brief_summary>
	<brief_title>Drugs Reduce Side Effects Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : I . Compare clinical efficacy safety Granisetron Metoclopramide combination Dexamethasone prophylaxis delay nausea vomit induced emetogenic cancer chemotherapy patient without emesis acute phase . OUTLINE : This randomize , double blind study . Patients stratify prior chemotherapy ( yes v ) , regular alcohol consumption ( yes v ) , prior chemotherapy regimen ( cisplatin/carboplatin v others ) . Patients receive dexamethasone granisetron mouth bid day 0 . Patients randomize receive either granisetron metoclopramide dexamethasone concurrently chemotherapy . Arm I : Patients receive granisetron mouth bid day 1-5 . Dexamethasone placebo administer mouth daily day 1-5 . Arm II : Patients receive metoclopramide mouth tid day 1-5 . Dexamethasone administer mouth daily day 1-5 . Patients must complete diary card daily 6 day . PROJECTED ACCRUAL : This study accrue 360 patient .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Scheduled receive first course highly emetogenic single day cancer chemotherapy regimens include : Cisplatin least 50 mg/m2 Carboplatin least 300 mg/m2 Dacarbazine least 500 mg/m2 Doxorubicin least 40 mg/m2 Epirubicin least 60 mg/m2 Ifosfamide least 1200 mg/m2 Cyclophosphamide least 600 mg/m2 PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Must able complete diary card ( fluent German , French , Italian ) No severe concurrent illness No etiology cause vomit , include : Gastrointestinal obstruction Hypercalcemia CNS metastases No active peptic ulceration No prior gastrointestinal bleeding due peptic ulcer No moderate severe nausea vomit 24 hour prior chemotherapy Not pregnant lactate PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 month since prior chemotherapy Concurrent etoposide fluorouracil allow ( day 15 ) No chemotherapy day 0 study Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent antiemetics No concurrent high dose benzodiazepine No concurrent psychotropic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>nausea vomit</keyword>
</DOC>